The Evolution of access to essential medicines for the treatment of HIV/AIDS

The Evolution of access to essential medicines for the treatment of HIV/AIDS

Tim Wilsdon
Life Sciences | Life Sciences Policy

The International Federation of Pharmaceutical Manufacturers and Associations asked CRA to review the evidence on the factors increasing access and the associated value of innovation across low and middle income countries for HIV/AIDS from 2000 to 2015. In the report, Tim Wilsdon and Lilian Li present an analysis of access to medicines and the value that these medicines deliver to different countries. The report focuses on six countries that have made progress in providing access to antiretroviral drugs including Botswana, Brazil, China, India, Rwanda, and South Africa and identifies a number of success factors. To read the report, click the link below. 

Download PDF